Vanda Pharmaceuticals | Des Atouts



Assets Changement Date
Acadia Pharmaceuticals USD 1.23B 93.19M 2025-06
Agios Pharmaceuticals USD 1.47B 84.28M 2025-06
Alnylam Pharmaceuticals USD 4.57B 352.21M 2025-06
Arrowhead Research USD 1.38B 192.89M 2025-06
AstraZeneca USD 112.42B 6.17B 2025-06
Bristol-Myers Squibb USD 94.68B 2.25B 2025-06
Eli Lilly USD 100.92B 11.53B 2025-06
Halozyme Therapeutics USD 2.05B 142.63M 2025-06
Insmed USD 2.48B 677.12M 2025-06
J&J USD 193.67B 13.57B 2025-03
Ligand Pharmaceuticals USD 948.6M 43.17M 2025-06
Merck USD 115.12B 1.98B 2025-03
Moderna USD 12.01B 694M 2025-06
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 206.1B 1.93B 2025-06
PTC Therapeutics USD 2.63B 21.23M 2025-06
Sanofi 124.96B 6.93B 2025-06
Takeda JPY 14T 243.81B 2025-06
Teva Pharmaceutical Industries USD 40.13B 1.72B 2025-06
Ultragenyx Pharmaceutical USD 1.31B 5.66M 2025-06
Veracyte USD 1.34B 28.69M 2025-06


Vanda Pharmaceuticals Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.